Experimental autoimmune myasthenia gravis in the mouse

Current Protocols in Immunology

Volumn , Issue SUPPL. 95, 2011, Pages

  Wu, Bo ^a   Goluszko, Elzbieta ^a   Huda, Ruksana ^a   Tüzün, Erdem ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Acetylcholine receptor; Experimental autoimmune myasthenia gravis; Myasthenia gravis; Neuromuscular junction

Indexed keywords

IMMUNOGLOBULIN G; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE MODEL; ELECTROMYOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; MOUSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; TORPEDO CALIFORNICA;

EID: 82455216717     PISSN: 19343671     EISSN: 1934368X     Source Type: Journal    
DOI: 10.1002/0471142735.im1523s95     Document Type: Article

References (36)

1. Aguis, M.A. and Richman, D.P. 1986. Suppression of development of experimental autoimmune myasthenia gravis with isogenic monoclonal antiidiotypic antibody. J. Immunol. 137:2195-2198.
2. Arafa, S., Gabin, F.S., Kishimoto, M., Adachi, A., and Blalock, E. 1996. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptor. J. Immunol. 157:386-392.
3. Bell, J., Smoot, S., Newly, C., Toyka, K., Rassenti, L., Smith, K., Hohlfeld, R., McDevitt, H.O., and Steinman, L. 1986. HLA-DQ β-chain polymorphism linked to myasthenia gravis. Lancet 8489:1058-1060.
4. Christadoss, P. 1989. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9:247-278.
5. Christadoss, P. and Dauphinee, M.J. 1986. Immunotherapy for myasthenia gravis: A murine model. J. Immunol. 136:2437-2440.
6. Christadoss, P., Lindstrom, J.M., Melvold, R.W., and Talal, N. 1985. Mutation at I-A β-chain prevents experimental autoimmune myasthenia gravis. Immunogenetics 21:33-38.
7. Christadoss, P., Lindstrom, J.M., Talal, N., Duvic, C.R., Kalantri, A., and Shenoy, M. 1986. Immune response gene control of lymphocyte proliferation induced by acetylcholine receptorspecific helper factor derived from lymphocytes of myasthenic mice. J. Immunol. 137:1845-1849.
8. Christadoss, P., Henderson, R., and Keve, S. 1991. Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 59:246-255.
9. Christadoss, P., Poussin, M., and Deng, C. 2000. Animal models of myasthenia gravis. Clin. Immunol. 94:75-87.
10. Conti-Fine, B.M., Milani, M., and Wang, W. 2008. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann. N.Y. Acad. Sci. 1132:193-209.
11. Cuatrecasas, P. and Anfinsen, C.B. 1971. Affinity chromatography. Annu. Rev. Biochem. 40:259-278.
12. Deng, C., Goluszko, E., Baron, S., Wu, B., and Christadoss, P. 1996. IFN-α therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:5675-5682.
13. Deng, C., Goluszko, E., Tüzün, E., Yang, H., and Christadoss, P. 2002. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169:1077-1083.
14. Drachman, D.B. 1994. Myasthenia gravis. N. Engl. J. Med. 330:1797-1810.
15. Goluszko, E., Deng, C., Poussin, M.A., and Christadoss, P. 2002. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J. Neuroimmunol. 122:85-93.
16. Hohlfeld, R., Toyka, K.V., Heininger, K., Grosse-Wilde, H., and Kalies, I. 1984. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 310:244-246.
17. Hohlfeld, R., Kalies, I., Kohleisen, B., Heininger, K., Conti-Tranconi, B.M., and Toyka, K.V. 1986. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 36:618-621.
18. Karlsson, E., Arnberg, H., and Eaker, D. 1971. Isolation of the principal neurotoxin of two Naja naja subspecies. Eur. J. Biochem. 21:1-16.
19. Kaul, R., Shenoy, M., Goluszko, E., and Christadoss, P. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:3152-3157.
20. Lennon, V.A., Lindstrom, J.M., and Seybold, M.E. 1975. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141:1365-1375.
21. Lindstrom, J., Einarson, B., and Tzartos, S. 1981. Production and assay of antibodies to acetylcholine receptor. Methods Enzymol. 74:432-460.
22. Melms, A., Oksenberg, J.R., Malcherek, G., Schoepfer, R., Muller, C.A., Lindstrom, J.M., and Steinman, L. 1993. T-cell receptor gene usage of acetylcholine receptor-specific Thelper cells. Ann. N.Y. Acad. Sci. 681:313-314.
23. Okumura, S., McIntosh, K., and Drachman, D.B. 1996. Oral administration of acetycholine receptors: Effects on experimental myasthenia gravis. Ann. Neurol. 36:704-713.
24. Poussin, M.A., Goluszko, E., Franco, J.U., and Christadoss, P. 2002. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J. Neuroimmunol. 125:51-58.
25. Rowin, J., Meriggioli, M.N., Tüzün, E., Leurgans, S., and Christadoss, P. 2004. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63:2390-2392.
26. Shenoy,M., Oshima,M., Atassi,M.Z., and Christadoss, P. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region of α146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:230-238.
27. Shenoy,M., Goluszko, E., and Christadoss, P. 1994. The pathogenic role of acetylcholine receptor alpha chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73:338-343.
28. Shenoy, M., Baron, S., Wu, B., Goluszko, E., and Christadoss, P. 1995. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. J. Immunol. 154:6203-6208.
29. Tüzün, E., Scott, B.G., Goluszko, E., Higgs, S., and Christadoss, P. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171:3847-3854.
30. Tüzün, E., Scott, B.G., Yang, H.,Wu, B., Goluszko, E., Guigneaux, M., Higgs, S., and Christadoss, P. 2004. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 172:5743-5752.
31. Tüzün, E., Saini, S.S., Ghosh, S., Rowin, J., Meriggioli, M.N., and Christadoss, P. 2006. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul. Disord. 16:137-143.
32. Tüzün, E., Li, J., Saini, S.S., Yang, H., and Christadoss, P. 2008. Targeting classical complement pathway to treat complement mediated autoimmune diseases. Adv. Exp. Med. Biol. 632:265-272.
33. Vincent, A. and Rothwell, P. 2004. Myasthenia gravis. Autoimmunity. 37:317-319.
34. Waldor, M.K., Sriram, S., McDevitt, H.O., and Steinman, L. 1983. In vivo therapy with monoclonal anti-IA antibody suppresses immune response to acetylcholine receptor. Proc. Natl. Acad. Sci. U.S.A. 80:2713-2717.
35. Wu, B., Shenoy, M., Goluszko, E., Kaul, R., and Christadoss, P. 1995. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis: Usage of multiple TCRBV genes in the H-2b strains. J. Immunol. 154:3603-3614.
36. Yang, H., Tüzün, E., Alagappan, D., Yu, X., Scott, B.G., Ischenko, A., and Christadoss, P. 2005. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J. Immunol. 175:2018-2025.